Published in Pharma Investments, Ventures and Law Weekly, February 12th, 2006
The preclinical studies were conducted by Cai Song, MD, PhD, associate professor in the Department of Biomedical Science, University of Prince Edward Island, Canada. Song holds a prestigious Canada Research Chair in Psychoneuroimmunology and is a leading authority in the field.
Preliminary results from these preclinical studies show that Miraxion has neuroprotective effects in PD. Full detailed data are expected to be published in a peer reviewed journal later this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly